Bellus Health Inc., of Laval, Quebec, said it entered into a share purchase agreement with Taro Pharmaceuticals Inc., of Brampton, Ontario, for the sale of their wholly owned subsidiary Thallion Pharmaceuticals Inc., including all the rights to the drug candidate Shigamab, a monoclonal antibody therapy being developed for the treatment of hemolytic uremic syndrome caused by Shiga toxin-producing E. coli.